Michelle B Offit1, Tianxia Wu2, Mary Kay Floeter3, Tanya J Lehky1. 1. EMG Section, NINDS, NIH, Bethesda, MD, USA. 2. Clinical Trials Unit, NINDS, NIH, Bethesda, MD, USA. 3. Motor Neuron Disorders Unit, NINDS, NIH, Bethesda, MD, USA.
Abstract
Objective: Electrical Impedance Myography (EIM) was used to evaluate disease progression in subjects with C9ORF72 expansion mutations and to assess correlations with Medical Research Council (MRC) Scale and revised ALS Functional Rating Scale (ALSFRS-R) measurements. Four types of clinical presentations were assessed; Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia (FTD) or other dementia, ALS-FTD, and asymptomatic (ASYMP). Methods: Subjects were divided into an ALS Group (ALS/ALS-FTD) and non-ALS Group (FTD/ASYMP) based on initial visit and evaluated at 0, 6, 18, and 30 months with EIM of 4 arm and 4 leg muscles, ALSFRS-R, and MRC scales. The change in EIM from baseline and correlation with the functional scale and strength testing were analyzed. Results: EIM 50kHz phase values significantly declined over time in the ALS group (n = 31) compared to the non-ALS group (FTD/ASYMP) (n = 19). In the ALS group, the decline in EIM was correlated with decline in the ALSFRS-R and MRC scores using within-subject correlations. Conclusion: In clinical trials with small populations of genetically associated ALS such as C9ORF-related ALS, EIM may be a useful quantitative biomarker. We did not detect decline in asymptomatic subjects, but longer term studies may detect early changes in this group.
Objective: Electrical Impedance Myography (EIM) was used to evaluate disease progression in subjects with C9ORF72 expansion mutations and to assess correlations with Medical Research Council (MRC) Scale and revised ALS Functional Rating Scale (ALSFRS-R) measurements. Four types of clinical presentations were assessed; Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia (FTD) or other dementia, ALS-FTD, and asymptomatic (ASYMP). Methods: Subjects were divided into an ALS Group (ALS/ALS-FTD) and non-ALS Group (FTD/ASYMP) based on initial visit and evaluated at 0, 6, 18, and 30 months with EIM of 4 arm and 4 leg muscles, ALSFRS-R, and MRC scales. The change in EIM from baseline and correlation with the functional scale and strength testing were analyzed. Results: EIM 50kHz phase values significantly declined over time in the ALS group (n = 31) compared to the non-ALS group (FTD/ASYMP) (n = 19). In the ALS group, the decline in EIM was correlated with decline in the ALSFRS-R and MRC scores using within-subject correlations. Conclusion: In clinical trials with small populations of genetically associated ALS such as C9ORF-related ALS, EIM may be a useful quantitative biomarker. We did not detect decline in asymptomatic subjects, but longer term studies may detect early changes in this group.
Authors: Peter J Dyck; Christopher J Boes; Donald Mulder; Clark Millikan; Anthony J Windebank; P James B Dyck; Raul Espinosa Journal: J Peripher Nerv Syst Date: 2005-06 Impact factor: 3.494
Authors: Seward B Rutkove; James B Caress; Michael S Cartwright; Ted M Burns; Judy Warder; William S David; Namita Goyal; Nicholas J Maragakis; Lora Clawson; Michael Benatar; Sharon Usher; Khema R Sharma; Shiva Gautam; Pushpa Narayanaswami; Elizabeth M Raynor; Mary Lou Watson; Jeremy M Shefner Journal: Amyotroph Lateral Scler Date: 2012-06-07
Authors: Seward B Rutkove; James B Caress; Michael S Cartwright; Ted M Burns; Judy Warder; William S David; Namita Goyal; Nicholas J Maragakis; Michael Benatar; Khema R Sharma; Pushpa Narayanaswami; Elizabeth M Raynor; Mary Lou Watson; Jeremy M Shefner Journal: Muscle Nerve Date: 2013-12-19 Impact factor: 3.217
Authors: Kin Mok; Bryan J Traynor; Jennifer Schymick; Pentti J Tienari; Hannu Laaksovirta; Terhi Peuralinna; Liisa Myllykangas; Adriano Chiò; Aleksey Shatunov; Bradley F Boeve; Adam L Boxer; Mariely DeJesus-Hernandez; Ian R Mackenzie; Adrian Waite; Nigel Williams; Huw R Morris; Javier Simón-Sánchez; John C van Swieten; Peter Heutink; Gabriella Restagno; Gabriele Mora; Karen E Morrison; Pamela J Shaw; Pamela Sara Rollinson; Ammar Al-Chalabi; Rosa Rademakers; Stuart Pickering-Brown; Richard W Orrell; Michael A Nalls; John Hardy Journal: Neurobiol Aging Date: 2011-09-16 Impact factor: 4.673